Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu
Trial record 1 of 1 for:    NCT 02387112
Previous Study | Return to List | Next Study

Early Versus Emergency Left Ventricular Assist Device Implantation in Patients Awaiting Cardiac Transplantation

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT02387112
Recruitment Status : Recruiting
First Posted : March 12, 2015
Last Update Posted : November 6, 2019
Sponsor:
Collaborators:
Deutsches Zentrum für Herz-Kreislauf-Forschung (DZHK)
Helmholtz Zentrum München
University Medicine Greifswald
University of Göttingen
Information provided by (Responsible Party):
German Heart Institute

Brief Summary:
The aim of the study is to assess whether, in patients who are listed for cardiac transplantation in transplantable (T) status, early implantation of a left ventricular assist device is superior to the current therapeutic strategy of medical heart failure therapy and assist device implantation only after serious deterioration of the patient's condition.

Condition or disease Intervention/treatment Phase
End Stage Heart Disease Device: Early VAD implantation Not Applicable

Detailed Description:

Heart transplantation is considered the gold-standard therapy for end-stage systolic heart failure but the shortage of donor hearts in Germany and other countries has led to widespread use of left ventricular assist devices (LVAD). Even on the transplant list, patients' condition often deteriorate due to worsening heart failure so that they need an LVAD as a bridge until transplantation. The high mortality (one in five patients on the waiting list dies within 1 year) reflects the severity of the disease. In comparison, technical progress has reduced the complication rate seen with assist devices and, according to recent data, mortality during LVAD support is low. Patient status prior to LVAD implantation is a strong indicator for postoperative outcome, i.e. patients in worse condition are more likely to develop complications. Thus, the comparison between the standard indication and early LVAD implantation (T-status) appears timely and clinically necessary.

The paucity of donor hearts necessitates the prospective evaluation of alternative treatment regimens. The aim of the study is to assess whether, in patients with end-stage heart failure awaiting cardiac transplantation, a strategy involving early LVAD implantation is superior to a strategy of conservative medical heart failure therapy and assist device implantation only after severe deterioration of heart failure.

The investigators expect to gain insights that will be trail-blazing for the future treatment of patients with heart failure on the transplantation waiting list, including aspects of their medical care. If the study hypotheses are confirmed, the treatment of these seriously ill patients could be, on the one hand, further optimized. On the other hand, positive economic effects are highly probable.

The results will form the basis of future guidelines for the treatment of this group of patients.

Thus the study will also make a contribution to solving the problem of the ever increasing number of patients on the waiting list as opposed to the decreasing willingness to donate organs for transplantation.

As a mean of quality control of the conducted study and to retrieve more data in this population all patients who fulfill the eligibility criteria of the study but do not consent to randomization are included in a standard treatment registry.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 200 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Early Versus Emergency Left Ventricular Assist Device Implantation in Patients Awaiting Cardiac Transplantation
Study Start Date : July 2015
Estimated Primary Completion Date : August 2022
Estimated Study Completion Date : December 2022

Resource links provided by the National Library of Medicine


Arm Intervention/treatment
Experimental: Early VAD implantation
The experimental intervention is early implantation of a left ventricular assist device (early VAD). Patients randomized to early VAD implantation will obtain a VAD within 28 days after randomization.
Device: Early VAD implantation
Implantation of a left ventricular assist device

No Intervention: Emergency VAD implantation
The control intervention is conservative heart failure treatment, with LVAD implantation in the case of worsening heart failure (emergency VAD). All patients randomized to the control intervention will be treated according to standard medical practice. In brief, these patients are closely monitored (scheduled regular visits to outpatient department depending on the patient's condition and at least every 6 months). If the condition worsens the patient may qualify for high urgency (HU) listing and/or for VAD implantation.



Primary Outcome Measures :
  1. Event-free survival [ Time Frame: Randomisation untill month 60 (60 months at the most, 48 months on average) ]
    The time to the composite end-point of all-cause death, high urgent cardiac transplantation, disabling stroke , HF hospitalizations (including emergency room HF visits >6 hrs).


Secondary Outcome Measures :
  1. Stroke [ Time Frame: Randomisation untill month 60 (60 months at the most, 48 months on average) ]
    Freedom from disabling and non-disabling strokes

  2. Listing for high-urgency (HU) cardiac transplantation [ Time Frame: Randomisation untill month 60 (60 months at the most, 48 months on average) ]
  3. Number of patients with de novo right heart failure measured by decreasing right heart ejection fraction, increasing central venous pressure and/or secondary organ failure needing catecholamines and/or right ventricular circulatory support [ Time Frame: Randomisation untill month 60 (60 months at the most, 48 months on average) ]
  4. Number of patients with hospitalizations due to device failure [ Time Frame: Randomisation untill month 60 (60 months at the most, 48 months on average) ]
  5. Number of patients with adverse events due to device failure [ Time Frame: Randomisation untill month 60 (60 months at the most, 48 months on average) ]
  6. Number of device infections requiring antibiotics and/surgical intervention [ Time Frame: Randomisation untill month 60 (60 months at the most, 48 months on average) ]
  7. Number of patients with major bleedings (needing >4 Units of blood) following VAD implantation and major bleedings due to anticoagulation therapy [ Time Frame: Randomisation untill month 60 (60 months at the most, 48 months on average) ]
    Bleeding needing hospitalisation, blood transfusion and/or surgical interventions

  8. Cardiovascular Death [ Time Frame: Randomisation untill month 60 (60 months at the most, 48 months on average) ]
  9. Number of patients suffering from secondary organ failure [ Time Frame: Randomisation untill month 60 (60 months at the most, 48 months on average) ]
    Time to event of renal and/or hepatic failure

  10. Maximum oxygen uptake (VO2 max) [ Time Frame: Measured every 6 months from randomisation untill month 60 (60 months at the most, 48 months on average) ]
  11. Heart failure survival score [ Time Frame: Measured every 6 months from randomisation untill month 60 (60 months at the most, 48 months on average) ]
  12. Seattle heart failure score [ Time Frame: Measured every 6 months from randomisation untill month 60 (60 months at the most, 48 months on average) ]
  13. New York Heart Association class (NYHA) [ Time Frame: Measured every 6 months from randomisation untill month 60 (60 months at the most, 48 months on average) ]
  14. Number of patients requiring urgent VAD implantation [ Time Frame: Randomisation untill month 60 (60 months at the most, 48 months on average) ]
  15. Rate of recurrent hospitalizations [ Time Frame: Randomisation untill month 60 (60 months at the most, 48 months on average) ]
  16. Number of patients receiving a donor heart [ Time Frame: Randomisation untill transplantation (60 months at the most, 48 months on average) ]
  17. VAD explantation due to myocardial recovery [ Time Frame: Randomisation untill month 60 (60 months at the most, 48 months on average) ]
    Time to event

  18. Short Form-36 (SF-36) [ Time Frame: Randomisation untill month 60 (60 months at the most, 48 months on average) ]
    Quality of life questionnaire (QoL)

  19. Minnesota Living with heart failure questionnaire (MLHFQ) [ Time Frame: Randomisation untill month 60 (60 months at the most, 48 months on average) ]
    Quality of life questionnaire (QoL)

  20. Mini-mental state examination (MMSE) [ Time Frame: Randomisation untill month 60 (60 months at the most, 48 months on average) ]
    Quality of life questionnaire (QoL)

  21. Quality-adjusted life year (QALY) [ Time Frame: Randomisation untill month 60 (60 months at the most, 48 months on average) ]


Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years to 65 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria

  • Patient (male or female) eligible for heart transplantation and accepted in T Status (transplantable) on the waiting list
  • Age 18 to 65 years
  • Signed informed consent
  • >30% 1-year mortality with the Seattle Heart Failure Model (SHFM) or at least three of the following criteria (a) to (f):

    1. cardiac index (CI) <2.5 l/min/m²
    2. pulmonary capillary wedge pressure >15 mmHg
    3. maximal oxygen uptake (VO2max) ≤10.0 ml/kg/min or ≤12.0 ml/kg/min in patients intolerant of a ß-blocker
    4. ratio of minute ventilation (VE) to carbon dioxide (VCO2) production (VE/VCO2) slope of >35
    5. at least two hospitalizations for heart failure within the previous 12 months
    6. documented increase of brain natriuretic peptide (BNP) or NTproBNP levels despite optimal medical therapy

Exclusion Criteria

  • Listing for transplantation of other organs in addition to heart
  • Previous cardiac surgeries (other than pacemaker or ICD surgeries)
  • Contraindications to assist device implantation (e.g. mechanical aortic valve, aortic insufficiency)
  • Contraindications to anticoagulation
  • Expected need for a right ventricular assist device/biventricular support expected (e.g. due to tricuspid valve insufficiency grade 3+, right ventricular ratio short/long axis ≥0.6, ratio of right to left ventricular end-diastolic diameter (RVEDD/LVEDD) >0.72, restrictive cardiomyopathy)
  • Presence of catecholamine support or intra-aortic balloon counterpulsation (IABP)
  • Overt infections
  • Fixed pulmonary hypertension (i.e. pulmonary arterial pressure (PAP) >60 mmHg and mean transpulmonary gradient (TPG) >15 mmHg or pulmonary vascular resistance (PVR) >6 Wood units despite optimal medical treatment)
  • Renal insufficiency (glomerular filtration rate (GFR) <30ml/min or need for hemodialysis or hemofiltration)
  • Significant coagulopathies
  • Systemic lupus erythematosus, sarcoid, or amyloidosis that has multisystem involvement and is still active
  • Drug abuse and/or alcohol abuse
  • Incompliance
  • Elevated panel reactivity levels of >50 %
  • Pregnancy or breast feeding in women
  • Participation in other investigational trials

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02387112


Contacts
Layout table for location contacts
Contact: Christoph Knosalla, MD, PhD ++49 30 4593 ext 2000 knosalla@dhzb.de
Contact: Sabine Hübler, MD, MBA ++49 30 4593 ext 2201 shuebler@dhzb.de

Locations
Show Show 20 study locations
Sponsors and Collaborators
German Heart Institute
Deutsches Zentrum für Herz-Kreislauf-Forschung (DZHK)
Helmholtz Zentrum München
University Medicine Greifswald
University of Göttingen
Investigators
Layout table for investigator information
Principal Investigator: Volkmar Falk, MD, PhD German Heart Institute Berlin Germany
Layout table for additonal information
Responsible Party: German Heart Institute
ClinicalTrials.gov Identifier: NCT02387112    
Other Study ID Numbers: DZHK VAD Study
VAD Study Germany ( Other Grant/Funding Number: DZHK/BMBF Germany )
First Posted: March 12, 2015    Key Record Dates
Last Update Posted: November 6, 2019
Last Verified: November 2019
Keywords provided by German Heart Institute:
End stage heart disease
Ventricular assist device
Additional relevant MeSH terms:
Layout table for MeSH terms
Heart Diseases
Emergencies
Disease Attributes
Pathologic Processes
Cardiovascular Diseases